米诺地尔搽剂

Search documents
京东健康CEO金恩林辞职;爱美客子公司两款米诺地尔搽剂获批上市
Mei Ri Jing Ji Xin Wen· 2025-09-30 07:03
点评:作为公司核心高管,金恩林的职务变动可能引发市场对管理层稳定性的短期担忧。不过,京东健 康迅速任命曹冬为新的执行董事和首席执行官,显示出公司应对管理层变动的高效性,有助于稳定市场 信心。 NO.3"早筛第一股"诺辉健康面临摘牌风险 近日,曾被誉为"癌症早筛第一股"的诺辉健康,已经在港交所连续停牌18个月了。按照交易所规定,公 司可能因此被强制退市。2023年8月,一份做空报告称诺辉健康通过不断压货方式,营造九成虚假销售 收入,次年3月,公司审计机构德勤拒绝为其财报背书并提出质疑,导致股票被强制停牌。 丨 2025年9月30日星期二丨 NO.1中国首个获批治疗PFIC的非手术靶向药物上市 近日,益普生宣布其罕见病创新药"蓓尔唯"(通用名:奥德昔巴特胶囊)在中国正式商业上市。去年12 月,该药物在国内获批用于治疗≥6月龄的PFIC患者的瘙痒,是目前中国首个且唯一获批治疗PFIC领域 的非手术靶向药物,目前已被纳入3个省市惠民保国内特药目录及11个省市惠民保海外特药目录。 点评:PFIC是一种罕见的遗传性疾病,发病率为(1~2)/10万,多在新生儿期或1岁以内发病。作为PFIC 的一线治疗药物,奥德昔巴特是目前 ...
京东健康CEO金恩林辞职;爱美客子公司两款米诺地尔搽剂获批上市|医药早参
Mei Ri Jing Ji Xin Wen· 2025-09-30 07:01
Group 1 - The first non-surgical targeted drug for treating PFIC, "Bai Er Wei" (generic name: Odevixibat capsules), has been officially launched in China, marking a significant breakthrough in the accessibility of treatment options for PFIC patients [1] - PFIC is a rare genetic disease with an incidence rate of (1-2)/100,000, typically manifesting in newborns or infants under one year old [1] - Odevixibat is the first and only approved non-surgical targeted drug for PFIC in China, which has been included in the domestic and overseas special drug directories of several provinces [1] Group 2 - JD Health's CEO, Jin Enlin, has resigned for family reasons, effective September 29, with a swift appointment of Cao Dong as the new CEO, indicating the company's efficient management response [2] - The resignation of key executives may raise short-term concerns regarding management stability, but the prompt succession plan aims to maintain market confidence [2] Group 3 - Nohui Health, known as the "first stock in cancer early screening," faces delisting risks after being suspended from trading for 18 months due to a short-selling report alleging inflated sales revenue [3] - The company's auditor, Deloitte, refused to endorse its financial statements, leading to the trading suspension, which could severely impact its future business expansion and fundraising efforts [3] Group 4 - Aimeike's subsidiary has received approval for two minoxidil topical solutions (2% and 5%) from the National Medical Products Administration, expanding its product offerings in the hair loss treatment sector [4] - The introduction of these products is expected to create new revenue growth opportunities for Aimeike and enhance its competitive position in the market [4] - This development reflects Aimeike's strength in research and product innovation, which may boost investor confidence and drive stock price appreciation [4]
国家发改委:推动智能终端和智能体市场扩容 DeepSeek
Xin Lang Cai Jing· 2025-09-30 00:07
Market Dynamics - The National Development and Reform Commission emphasizes the need to enhance macro policies to address economic challenges and aims to expand the smart terminal and intelligent body market by developing new policy guidelines [1] - The Nasdaq Golden Dragon China Index rose by 2.03%, with notable increases in popular Chinese stocks such as Bilibili, Alibaba, and New Oriental, which all rose over 4% [1] Company Developments - Yu Chengdong has been appointed as the IRB Director of Huawei, indicating a strategic focus on AI for the next decade, with resources being directed towards AI chips, large models, and smart vehicles [3] - Cambrian Technology announced compatibility with DeepSeek-V3.2-Exp and open-sourced the vLLM-MLU inference engine, which significantly reduces training and inference costs in long-sequence scenarios [4] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.10% [5] - Xiamen Tungsten New Energy signed a strategic cooperation framework agreement with Zhongwei Co., establishing a long-term partnership for raw material supply chains in solid-state lithium battery materials [5] - Sairus has completed the payment for acquiring a 10% stake in Yingwang Intelligent Technology from Huawei, totaling 11.5 billion yuan [6] - Hengwei Technology plans to acquire 75% of Shuhang Technology, focusing on AI application products and solutions [7] - DiAo Micro is planning to acquire equity in Rongpai Semiconductor, with stock trading suspended during the process [8] - Galun Electronics intends to purchase 100% of Chengdu Ruicheng Semiconductor and 45.64% of Naneng Microelectronics, with a total transaction value of approximately 2.174 billion yuan [9] - Suochen Technology plans to acquire 60% of Likong Technology, with the total transaction price set at 192 million yuan [10] - Weide Information announced a preliminary transfer price of 40.33 yuan per share for its stock, with significant interest from institutional investors [11] - Aimeike received a drug registration certificate for Minoxidil lotion, a treatment for male pattern baldness [12] Technological Advances - The world's largest supergravity centrifuge has been officially launched, contributing to major scientific research and development [12] - A new method combining AI and remote sensing has been developed to identify optimal grass planting areas in northern arid regions, aiding ecological protection and agricultural development [12]
爱美客:子公司取得米诺地尔搽剂《药品注册证书》
Zhi Tong Cai Jing· 2025-09-29 13:50
Core Viewpoint - Aimer (300896.SZ) announced that its wholly-owned subsidiary, Beijing Nobot Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for the registration of Minoxidil topical solution in 2% and 5% concentrations, which are non-prescription dermatological medications [1] Group 1 - The 2% formulation is indicated for the treatment of androgenetic alopecia and alopecia areata [1] - The 5% formulation is restricted for use by males only, also for the treatment of androgenetic alopecia and alopecia areata [1] - Minoxidil is a peripheral vasodilator that, when used topically over a long period, can stimulate hair growth in male patients suffering from androgenetic alopecia and alopecia areata [1]
爱美客(300896.SZ):米诺地尔搽剂取得药品注册证书
Ge Long Hui A P P· 2025-09-29 13:04
格隆汇9月29日丨爱美客(300896.SZ)公布,全资子公司北京诺博特生物科技有限公司(简称"诺博特")收 到国家药品监督管理局核准签发的规格分别为2%和5%的米诺地尔搽剂《药品注册证书》,米诺地尔搽 剂为皮肤科用药类非处方药药品。2%规格用于治疗男性型脱发和斑秃;5%规格仅限男性使用,用于治 疗男性型脱发和斑秃。米诺地尔是一种周围血管舒张药,局部长期使用时,可刺激男性型脱发和斑秃患 者的毛发生长。 ...
A股公告精选 | 英联股份(002846.SZ)前三季度业绩同比大增超15倍
智通财经网· 2025-09-29 12:18
Group 1 - Yinglian Co., Ltd. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531% to 1673% [1] - China CNR Corporation signed major contracts totaling approximately 54.34 billion yuan, accounting for 22% of its expected revenue for 2024 [1] - Shengmei Shanghai reported a total order amount of 9.072 billion yuan, a year-on-year increase of 34.1% [2] Group 2 - Fulian Precision plans to increase capital in its subsidiary Jiangxi Shenghua with a total investment of 35.63 billion yuan, which is expected to constitute a major asset restructuring [3] - Aimeike has obtained a drug registration certificate for Minoxidil topical solution, which is used for treating male pattern baldness [4] - Guolin Technology is planning to acquire 91.07% of Kailianjie’s equity for cash, which is expected to constitute a major asset restructuring [5] Group 3 - Baicheng Co. plans to purchase 55% of Shanghai Canxi Engineering Equipment Co. and will suspend trading of its stock starting September 30, 2025 [6][7] - Diaowei is planning to acquire equity in Rongpai Semiconductor and has suspended trading of its stock [8] - Xiatun New Energy signed a strategic cooperation framework agreement with Zhongwei Co. to establish a long-term partnership in the supply chain for solid-state lithium battery materials [9] Group 4 - Lingyi Zhi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy [10] - Baicheng Pharmaceutical received clinical trial approval for its innovative drug BIOS-0623-Z4, which targets cancer pain treatment [11] - Weide Information announced a preliminary transfer price of 40.33 yuan per share, representing a 26% discount to its closing price [12] Group 5 - Huayou Cobalt's subsidiary signed contracts with LGES for the supply of 76,000 tons of ternary precursor materials and 88,000 tons of ternary cathode materials from 2026 to 2030 [13] - Hubei Energy signed a cooperation agreement with the Xiangyang Municipal Government to invest 26.7 billion yuan in clean energy projects [14]
爱美客(300896.SZ):子公司取得米诺地尔搽剂《药品注册证书》
智通财经网· 2025-09-29 12:18
据悉,米诺地尔搽剂为皮肤科用药类非处方药药品。2%规格用于治疗男性型脱发和斑秃;5%规格仅限男 性使用,用于治疗男性型脱发和斑秃。米诺地尔是一种周围血管舒张药,局部长期使用时,可刺激男性 型脱发和斑秃患者的毛发生长。 智通财经APP讯,爱美客(300896.SZ)公告,近日,公司全资子公司北京诺博特生物科技有限公司("诺博 特")收到国家药品监督管理局核准签发的规格分别为2%和5%的米诺地尔搽剂《药品注册证书》。 ...
爱美客:子公司诺博特取得米诺地尔搽剂药品注册证书
Zheng Quan Shi Bao Wang· 2025-09-29 10:48
人民财讯9月29日电,爱美客(300896)9月29日公告,近日,公司全资子公司北京诺博特生物科技有限 公司(简称"诺博特")收到国家药品监督管理局核准签发的规格分别为2%和5%的米诺地尔搽剂《药品 注册证书》。米诺地尔搽剂为皮肤科用药类非处方药药品。2%规格用于治疗男性型脱发和斑秃;5%规 格仅限男性使用,用于治疗男性型脱发和斑秃。米诺地尔是一种周围血管舒张药,局部长期使用时,可 刺激男性型脱发和斑秃患者的毛发生长。 ...
爱美客:子公司米诺地尔搽剂获得药品注册证书
Xin Lang Cai Jing· 2025-09-29 10:48
爱美客9月29日公告,公司全资子公司北京诺博特生物科技有限公司获得国家药品监督管理局核准签发 的米诺地尔搽剂《药品注册证书》。米诺地尔搽剂为皮肤科用药类非处方药药品。2%规格用于治疗男 性型脱发和斑秃;5%规格仅限男性使用,用于治疗男性型脱发和斑秃。 ...
爱美客:全资子公司取得药品注册证书
Mei Ri Jing Ji Xin Wen· 2025-09-29 10:46
每经AI快讯,爱美客(SZ 300896,收盘价:182.2元)9月29日晚间发布公告称,近日,爱美客技术发 展股份有限公司全资子公司北京诺博特生物科技有限公司收到国家药品监督管理局核准签发的规格分别 为2%和5%的米诺地尔搽剂《药品注册证书》。 2024年1至12月份,爱美客的营业收入构成为:医疗器械行业占比99.9%,其他行业占比0.1%。 截至发稿,爱美客市值为551亿元。 每经头条(nbdtoutiao)——农夫大战怡宝,抢到更多蛋糕的却是宗馥莉!农夫绿瓶上市后,怡宝上 演"滑铁卢":市占率大跌近5个百分点 (记者 王晓波) ...